ERBB2 and neoplasm: HER2, an oncogene encoding a growth factor receptor, is a transmembrane glycoprotein that regulates cell proliferation and differentiation.66,67 Numerous studies have indicated the overexpression of HER2 in many epithelium-derived malignancies.63,68–71 Therefore, HER2 is viewed as a promising target for many solid tumors.72 To test the antitumor potential of CAR T therapy for HER2-positive tumor cells, ten CAR T clinical trials involving HER2 were carried out in China, among which the first one was posted in September 2013.